Alembic Ltd

Alembic Ltd

₹ 83.4 3.86%
28 Mar - close price
About

Alembic Limited is engaged in the businesses of Pharmaceuticals, Real Estate, and Power Assets. The company was started in 1907 as the flagship company of the Alembic Group. In 2010, the company demerged its core pharmaceutical business (formulations) into a wholly-owned subsidiary, Alembic Pharma Ltd and after the demerger, APL became the flagship company of the Alembic Group.
With its registered office in Vadodra, Alembic Ltd currently holds a 28.41% stake in Alembic Pharma Ltd and a 19.01% stake in another group entity Paushak Limited.[1]

Key Points

Business Portfolio:
A) Pharmaceuticals:
The company deals in the bulk drugs manufacturing and marketing of APIs like Estolate, Biphenyl Valine Oxalate, Venlafaxine, etc. AL is also engaged in R&D activity. [1]

  • Market Cap 2,143 Cr.
  • Current Price 83.4
  • High / Low 108 / 56.3
  • Stock P/E 24.6
  • Book Value 32.8
  • Dividend Yield 2.64 %
  • ROCE 10.2 %
  • ROE 9.45 %
  • Face Value 2.00

Pros

  • Company is almost debt free.
  • Company is expected to give good quarter
  • Company has been maintaining a healthy dividend payout of 54.6%

Cons

  • Stock is trading at 2.55 times its book value
  • Tax rate seems low
  • Company has a low return on equity of 7.18% over last 3 years.
  • Earnings include an other income of Rs.44.0 Cr.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Realty Industry: Construction

Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
14 29 21 19 19 17 21 36 30 36 36 31 38
10 25 17 17 15 15 16 26 20 23 26 22 25
Operating Profit 4 4 4 3 3 3 5 10 10 13 10 10 13
OPM % 27% 14% 20% 14% 18% 16% 23% 29% 33% 35% 28% 31% 35%
3 2 2 81 2 4 1 59 2 -9 3 48 2
Interest 0 0 0 0 0 0 0 0 0 0 0 0 0
Depreciation 1 1 1 1 1 1 2 2 2 2 2 2 3
Profit before tax 5 5 5 83 4 6 4 68 11 2 11 56 13
Tax % 17% 20% 20% 11% 3% 20% 10% 10% 1% -72% 13% 8% 10%
4 4 4 73 4 5 4 61 10 4 9 51 11
EPS in Rs 0.18 0.14 0.15 2.86 0.15 0.18 0.14 2.37 0.41 0.17 0.37 2.00 0.44
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
121 179 154 144 134 147 125 124 74 72 76 123 141
122 164 126 134 128 140 114 106 70 62 63 85 95
Operating Profit -1 16 28 10 6 7 11 18 4 11 13 38 46
OPM % -1% 9% 18% 7% 5% 5% 9% 15% 5% 15% 17% 31% 32%
4 10 18 21 25 25 37 29 93 10 89 54 44
Interest 5 5 4 1 0 0 0 0 0 0 0 0 0
Depreciation 11 10 8 6 6 5 4 3 3 4 4 6 8
Profit before tax -14 11 33 23 25 27 44 45 94 17 97 85 82
Tax % 10% -4% 12% -3% 2% -3% 5% 8% 0% 19% 12% 7%
-12 11 30 24 25 27 42 41 94 13 86 79 76
EPS in Rs -0.46 0.43 1.11 0.90 0.93 1.03 1.56 1.60 3.64 0.52 3.34 3.09 2.98
Dividend Payout % -0% 23% 14% 17% 16% 19% 13% 12% 16% 38% 54% 71%
Compounded Sales Growth
10 Years: -4%
5 Years: 0%
3 Years: 19%
TTM: 35%
Compounded Profit Growth
10 Years: 22%
5 Years: 18%
3 Years: -2%
TTM: 9%
Stock Price CAGR
10 Years: 20%
5 Years: 20%
3 Years: -6%
1 Year: 48%
Return on Equity
10 Years: 9%
5 Years: 9%
3 Years: 7%
Last Year: 9%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Sep 2023
Equity Capital 27 27 53 53 53 53 53 51 51 51 51 51 51
Reserves 170 179 177 211 295 314 395 361 432 775 962 778 790
103 25 22 -0 9 -0 -0 -0 -0 0 -0 -0 5
91 113 104 91 64 81 73 57 51 109 130 119 139
Total Liabilities 391 344 356 356 421 449 522 470 534 936 1,144 948 986
195 185 178 169 146 171 179 209 225 261 294 318 341
CWIP 0 3 2 2 -0 0 -0 -0 3 6 0 0 1
Investments 23 23 21 35 150 189 276 205 197 581 726 503 472
173 132 155 149 124 89 67 55 109 88 124 127 172
Total Assets 391 344 356 356 421 449 522 470 534 936 1,144 948 986

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
-59 80 -10 22 10 52 24 22 5 -1 -22 35
-5 12 18 5 -5 -47 -23 68 57 -35 23 11
65 -94 -8 -25 -5 -5 -3 -89 -6 -15 -6 -46
Net Cash Flow 0 -2 -0 2 -0 -0 -2 1 56 -52 -5 -0

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 48 37 66 122 76 54 74 40 44 66 72 67
Inventory Days 646 351 1,924 880 659 438 247 289 411 2,112 2,885 5,118
Days Payable 176 173 659 200 144 128 125 202 151 675 635 993
Cash Conversion Cycle 518 215 1,330 801 591 364 195 126 304 1,504 2,322 4,191
Working Capital Days 324 93 200 235 172 39 20 13 28 98 231 127
ROCE % -2% 6% 16% 9% 8% 8% 10% 10% 21% 2% 10% 10%

Shareholding Pattern

Numbers in percentages

Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
70.88% 70.88% 70.88% 70.88% 70.88% 70.88% 70.88% 70.88% 70.88% 70.88% 70.88% 70.88%
1.60% 1.30% 1.23% 1.19% 1.12% 1.08% 0.83% 0.82% 0.70% 0.72% 0.85% 0.89%
4.34% 4.75% 4.89% 5.17% 4.69% 4.29% 4.12% 3.94% 3.94% 3.93% 3.40% 0.04%
23.18% 23.07% 23.00% 22.76% 23.31% 23.75% 24.16% 24.34% 24.48% 24.46% 24.87% 28.17%
No. of Shareholders 67,23877,20180,56178,38180,13583,00683,61283,63082,33981,73282,94794,012

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents